Skip to content
You are now leaving to visit

Akcea Completes Enrollment in Phase 2b Study of AKCEA-APO(a)-LRx

CAMBRIDGE, Mass. , Feb. 07, 2018 (GLOBE NEWSWIRE) — Akcea Therapeutics, Inc. (NASDAQ:AKCA), today announced it had completed enrollment of a Phase 2b clinical study of investigational drug AKCEA-APO(a)-L Rx . Akcea is conducting the study in patients with high Lp(a) and established cardiovascular